Author: Smead Capital Management

Interest Rates Affect on Intrinsic Value

We at Smead Capital Management believe in the value of compounded returns. They are the friend of the long-duration common stock investor, especially when considering the intrinsic value of a company. With so much chatter among investors, the media and analysts over when the Federal Reserve will increase interest rates, we would like to share with you how we think about and use prevailing interest rates in security analysis. Together with earnings growth estimates and longevity, the discount interest rate is a cornerstone of calculating the intrinsic value of a company.

⟶ Keep Reading

Bloomberg Asia: Cole Smead discusses the US economy

 In This Era, Nobody Wants Stocks First Up hosted by Angie Lau For a link to the video go to www.bloomberg.com. The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no

⟶ Keep Reading

Citywire Global: Cole Smead discusses US Equity Market Valuations

Strength of US economy will shock investors, says boutique manager Citywire Global hosted by Chris Sloley For more information go to www.citywireglobal.com.   The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance

⟶ Keep Reading

CNBC Europe: Cole Smead on Financials

 We wouldn’t touch Citigroup Squawk Box Europe hosted by Stephen Sedgwick & Karen Tso For more information go to www.cnbc.com.   The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is

⟶ Keep Reading

WSJ: Tony Scherrer on the U.S. Markets

U.S. Stocks End Higher By Corrie Driebusch For more information go to www.wsj.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. The securities identified and

⟶ Keep Reading

Barron’s: Tony Scherrer discusses Pfizer

 Pfizer: Juicy Dividend, Strong Pipeline, Big Gains By Johanna Bennett For more information go to www.barrons.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. The

⟶ Keep Reading
Scroll to Top